A new analysis of the eight major randomized breast cancer screening trials suggests that the risk of overdiagnosis from mammography may have been substantially overestimated for decades. Rather than the 30% to 50% rates cited in some earlier research, the reanalysis points to an overdiagnosis rate below 5%.
Overdiagnosis occurs when a screening test detects a cancer that would never have caused symptoms or threatened a woman's life during her lifetime. Because doctors cannot yet reliably distinguish these indolent tumors from aggressive ones, many patients undergo surgery, radiation, and hormone therapy they may not have needed. The concern has fueled a long-running debate over when and how often women should be screened.
The researchers behind the new work reexamined all eight major randomized screening trials and adjusted for three factors they say earlier analyses handled inconsistently: differences in follow-up time, differences in screening frequency, and the extent to which screening continued after the trials formally ended. When those variables were accounted for, the results converged on a much lower estimate.
The findings do not resolve every question about mammography, but they challenge a widely repeated statistic that has influenced clinical guidelines, patient counseling, and public health messaging. If the overdiagnosis rate is indeed below 5%, the balance of benefits and harms from routine screening shifts meaningfully.
Breast cancer remains one of the most common cancers among women in the United States, and mammography is the primary tool for detecting it early. Screening programs are credited with helping reduce mortality, but they also carry risks of false positives, unnecessary biopsies, and anxiety. Overdiagnosis has been the most contested of those harms because it is difficult to measure directly.
The new analysis suggests that some of the variation in earlier estimates came from methodological choices rather than from the underlying biology of the disease. By standardizing how follow-up and post-trial screening were counted, the researchers found that the trials told a more consistent story than the previous literature implied.
The work is likely to be scrutinized by epidemiologists, oncologists, and patient advocates who have argued for years about how to communicate screening trade-offs. Some previous estimates approaching 30% to 50% have been used to question the value of routine mammography, while other researchers have argued those figures were inflated by flawed assumptions.
For now, the analysis adds a significant new data point to a debate that affects millions of women and the clinicians who counsel them. It does not settle how screening should be personalized, but it suggests that the risk of overdiagnosis may be smaller than many patients and doctors have been told.
The researchers' approach — revisiting the full set of randomized trials with a unified method — also highlights how sensitive cancer screening statistics can be to the way studies are analyzed. Small differences in how long patients are followed or how often they are screened can produce large differences in reported overdiagnosis rates.
Further work will be needed to confirm the findings and to translate them into practical guidance. In the meantime, the analysis offers a more optimistic picture of mammography's trade-offs than the one that has dominated public discussion for a generation.